Sleep endocrine effects of the 11-beta-hydroxysteroiddehydrogenase inhibitor metyrapone.

Standard

Sleep endocrine effects of the 11-beta-hydroxysteroiddehydrogenase inhibitor metyrapone. / Jahn, Holger; Kiefer, Falk; Schick, Mildred; Yassouridis, Alexander; Steiger, Axel; Kellner, Michael; Wiedemann, Klaus.

in: SLEEP, Jahrgang 26, Nr. 7, 7, 2003, S. 823-829.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Jahn, H, Kiefer, F, Schick, M, Yassouridis, A, Steiger, A, Kellner, M & Wiedemann, K 2003, 'Sleep endocrine effects of the 11-beta-hydroxysteroiddehydrogenase inhibitor metyrapone.', SLEEP, Jg. 26, Nr. 7, 7, S. 823-829. <http://www.ncbi.nlm.nih.gov/pubmed/14655915?dopt=Citation>

APA

Jahn, H., Kiefer, F., Schick, M., Yassouridis, A., Steiger, A., Kellner, M., & Wiedemann, K. (2003). Sleep endocrine effects of the 11-beta-hydroxysteroiddehydrogenase inhibitor metyrapone. SLEEP, 26(7), 823-829. [7]. http://www.ncbi.nlm.nih.gov/pubmed/14655915?dopt=Citation

Vancouver

Jahn H, Kiefer F, Schick M, Yassouridis A, Steiger A, Kellner M et al. Sleep endocrine effects of the 11-beta-hydroxysteroiddehydrogenase inhibitor metyrapone. SLEEP. 2003;26(7):823-829. 7.

Bibtex

@article{09586a2e661d4841baffbe05599b8b21,
title = "Sleep endocrine effects of the 11-beta-hydroxysteroiddehydrogenase inhibitor metyrapone.",
abstract = "STUDY OBJECTIVES: Besides regulating hormone secretion, steroids also modulate sleep architecture in specific ways. To simulate a state of altered glucocorticoid- and mineralocorticoid-receptor occupation, we administered metyrapone, an 11-beta-hydroxylase inhibitor, that blocks adrenal cortisol synthesis and inhibits the 11-beta-hydroxysteroiddehydrogenase type-1 enzyme in the central nervous system and investigated endocrine changes and the sleep electroencephalogram. DESIGN: Each volunteer spent 4 nights in the sleep laboratory, the first of which served to habituate the subject to the conditions in the laboratory. The volunteers underwent 3 trial conditions in random order and in a single-blind design receiving 2 doses of metyrapone (4.5 g or 6.0 g) or placebo on the day before the sleep electroencephalogram recordings. SETTING: Sleep laboratory. PARTICIPANTS: 8 healthy male volunteers. MEASUREMENTS AND RESULTS: The corticotropin secretion was significantly enhanced by metyrapone, while the cortisol secretion remained largely unchanged. Growth hormone, progesterone, and dehydroepiandrosterone concentrations were also significantly increased by both doses. Metyrapone induced a pronounced reduction in slow-wave sleep and had slight but nonlinear effects upon rapid eye movement sleep. Parameters of sleep quality were not different between groups. CONCLUSIONS: Metyrapone induces pronounced effects on hormonal secretion and the sleep electroencephalogram. These results are in part comparable to those from experiments with the administration of corticotropin-releasing hormone and with experiments that deplete mineralocorticoid receptors. The findings may be explained by altered steroid synthesis proximal to the enzyme block. Metyrapone exerts not only effects upon adrenocortical steroid synthesis, but also important extra-adrenal effects on central corticosteroid metabolism.",
author = "Holger Jahn and Falk Kiefer and Mildred Schick and Alexander Yassouridis and Axel Steiger and Michael Kellner and Klaus Wiedemann",
year = "2003",
language = "Deutsch",
volume = "26",
pages = "823--829",
journal = "SLEEP",
issn = "0161-8105",
publisher = "American Academy of Sleep Medicine",
number = "7",

}

RIS

TY - JOUR

T1 - Sleep endocrine effects of the 11-beta-hydroxysteroiddehydrogenase inhibitor metyrapone.

AU - Jahn, Holger

AU - Kiefer, Falk

AU - Schick, Mildred

AU - Yassouridis, Alexander

AU - Steiger, Axel

AU - Kellner, Michael

AU - Wiedemann, Klaus

PY - 2003

Y1 - 2003

N2 - STUDY OBJECTIVES: Besides regulating hormone secretion, steroids also modulate sleep architecture in specific ways. To simulate a state of altered glucocorticoid- and mineralocorticoid-receptor occupation, we administered metyrapone, an 11-beta-hydroxylase inhibitor, that blocks adrenal cortisol synthesis and inhibits the 11-beta-hydroxysteroiddehydrogenase type-1 enzyme in the central nervous system and investigated endocrine changes and the sleep electroencephalogram. DESIGN: Each volunteer spent 4 nights in the sleep laboratory, the first of which served to habituate the subject to the conditions in the laboratory. The volunteers underwent 3 trial conditions in random order and in a single-blind design receiving 2 doses of metyrapone (4.5 g or 6.0 g) or placebo on the day before the sleep electroencephalogram recordings. SETTING: Sleep laboratory. PARTICIPANTS: 8 healthy male volunteers. MEASUREMENTS AND RESULTS: The corticotropin secretion was significantly enhanced by metyrapone, while the cortisol secretion remained largely unchanged. Growth hormone, progesterone, and dehydroepiandrosterone concentrations were also significantly increased by both doses. Metyrapone induced a pronounced reduction in slow-wave sleep and had slight but nonlinear effects upon rapid eye movement sleep. Parameters of sleep quality were not different between groups. CONCLUSIONS: Metyrapone induces pronounced effects on hormonal secretion and the sleep electroencephalogram. These results are in part comparable to those from experiments with the administration of corticotropin-releasing hormone and with experiments that deplete mineralocorticoid receptors. The findings may be explained by altered steroid synthesis proximal to the enzyme block. Metyrapone exerts not only effects upon adrenocortical steroid synthesis, but also important extra-adrenal effects on central corticosteroid metabolism.

AB - STUDY OBJECTIVES: Besides regulating hormone secretion, steroids also modulate sleep architecture in specific ways. To simulate a state of altered glucocorticoid- and mineralocorticoid-receptor occupation, we administered metyrapone, an 11-beta-hydroxylase inhibitor, that blocks adrenal cortisol synthesis and inhibits the 11-beta-hydroxysteroiddehydrogenase type-1 enzyme in the central nervous system and investigated endocrine changes and the sleep electroencephalogram. DESIGN: Each volunteer spent 4 nights in the sleep laboratory, the first of which served to habituate the subject to the conditions in the laboratory. The volunteers underwent 3 trial conditions in random order and in a single-blind design receiving 2 doses of metyrapone (4.5 g or 6.0 g) or placebo on the day before the sleep electroencephalogram recordings. SETTING: Sleep laboratory. PARTICIPANTS: 8 healthy male volunteers. MEASUREMENTS AND RESULTS: The corticotropin secretion was significantly enhanced by metyrapone, while the cortisol secretion remained largely unchanged. Growth hormone, progesterone, and dehydroepiandrosterone concentrations were also significantly increased by both doses. Metyrapone induced a pronounced reduction in slow-wave sleep and had slight but nonlinear effects upon rapid eye movement sleep. Parameters of sleep quality were not different between groups. CONCLUSIONS: Metyrapone induces pronounced effects on hormonal secretion and the sleep electroencephalogram. These results are in part comparable to those from experiments with the administration of corticotropin-releasing hormone and with experiments that deplete mineralocorticoid receptors. The findings may be explained by altered steroid synthesis proximal to the enzyme block. Metyrapone exerts not only effects upon adrenocortical steroid synthesis, but also important extra-adrenal effects on central corticosteroid metabolism.

M3 - SCORING: Zeitschriftenaufsatz

VL - 26

SP - 823

EP - 829

JO - SLEEP

JF - SLEEP

SN - 0161-8105

IS - 7

M1 - 7

ER -